Calypte Biomedical Presents Results of Its Rapid HIV-1/2 Field Trial Tests at the XV International AIDS Conference in Bangkok Overall Accuracy: Blood Rapid 100%, Oral Fluid Rapid 99.8%, Urine Rapid 99.6% PLEASANTON, Calif., July 15 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC:CYPT) (BULLETIN BOARD: CYPT) announced today that it has completed the initial field trials of its rapid products currently under development and has distributed that study data at the XV International AIDS Conference in Bangkok, Thailand. The results are based on a statistically significant number of patients conducted under a controlled clinical study at the Thai Red Cross Anonymous HIV Clinic in Bangkok, Thailand. The results are as follows: External validation trials of the Calypte blood, oral fluid and blood rapid HIV antibody assays began in April 2004 at the Thai Red Cross Anonymous HIV Clinic in Bangkok, Thailand. This study was completed in June 2004 and results have been provided to delegates of the XV International AIDS Conference currently in progress in Bangkok. This study tested a total of 1023 subjects, 392 seropositive subjects, including 37 seropositive subjects receiving anti-retroviral therapy, and 631 seronegative subjects. The true antibody status of these subjects was determined by testing of a blood sample using the standard testing method routinely used by the Anonymous Clinic for diagnostic testing. The Calypte blood rapid test was 100% concordant with the results of the standard blood tests. The Calypte oral fluid test demonstrated 99.5% sensitivity (390/392). The two false negative results were from two known positive subjects who were on anti-retroviral therapy. These patients are known to have diminished antibody levels and would not normally be seeking HIV diagnostic testing. The specificity of the oral fluid test was 100%. The Calypte urine assay was found to be 99.0% sensitive (388/392), 100% specific. The blood, oral fluid, and urine tests correctly identified 1023/1023, 1021/1023, and 1019/1023 for an overall accuracy of 100%, 99.8%, and 99.6%, respectively. "We are having a successful meeting at the XV International AIDS Conference in Bangkok, Thailand this week, presenting the results of our field trials of our Thailand studies covering over 1,000 subjects," said Dr. Richard George, Calypte's President and Chief Executive Officer. "I am very pleased with the performance of these assays in their initial field testing. The performance of the blood rapid test is on a par with the best laboratory and rapid HIV antibody tests currently on the market. The Calypte assays that test non-invasive alternative fluids showed performance comparable to or better than other such assays currently available. Even though we have other validation studies either in progress or pending and we continue to improve these assays, this study validates our decision to begin manufacturing and commercialization of these assays for the international market. We believe the availability of these safe, accurate, and economical assays will increase the acceptance of HIV testing and will lead to more people knowing their HIV status and being enrolled in treatment programs." About Calypte Biomedical: Calypte Biomedical Corporation, headquartered in Pleasanton, California, is a public healthcare company dedicated to the development and commercialization of in vitro diagnostic tests, primarily for the detection of antibodies to Human Immunodeficiency Virus (HIV), and other sexually transmitted and infectious diseases. Calypte's currently marketed laboratory- based tests include an enzyme immunoassay (EIA) HIV-1 antibody screening test and an HIV-1 antibody western blot supplemental test, the only two FDA-approved HIV-1 antibody tests for use on urine samples, as well as an FDA-approved serum HIV-1 antibody western blot supplemental test. Calypte is actively engaged in developing new test products for the rapid detection of HIV and other infectious diseases. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other infectious diseases may make important contributions to public health. Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2003 and its subsequent filings with the SEC. Company Contact: Investor Relations Contact: Dr. Richard George, Tim Clemensen, President and CEO Rubenstein Investor Relations Phone: 925-730-7200 Phone: 212-843-9337 Email: Email: DATASOURCE: Calypte Biomedical Corporation CONTACT: Dr. Richard George, President and CEO, +1-925-730-7200, ; or Investor Relations - Tim Clemensen of Rubenstein Investor Relations, +1-212-843-9337, Web site: http://www.calypte.com/

Copyright